Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda Maintenance in Metastatic Colorectal Cancer
NCT02060669Phase 3Terminated
- Sponsor
- Samsung Medical Center
- Start
- Jun 2010
- Primary completion
- May 2014
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Samsung Medical Center. Started Jun 2010; status: terminated.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02060669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060669.